Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells.

Molecular carcinogenesis - 1 Jul 2018

Gergely Joseph E, Dorsey Armond E, Dimri Goberdhan P, Dimri Manjari

Abstract excerpt

Polycomb group (PcG) protein BMI1 is an important regulator of oncogenic phenotype and is often overexpressed in several human malignancies including breast cancer. Aberrant expression of BMI1 is associated with metastasis and poor prognosis in cancer patients. At present, therapy reagents that can efficiently inhibit the expression of BMI1 are not very well known. Here, we report that Timosaponin A-III (TA-III),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Cellular Senescence
Share to MCF-7 Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Oncogenes

Share to Polycomb-Group Proteins

Share to Polycomb Repressive Complex 1

Share to Saponins

Share to Steroids

Source

Open in PubMed Open full text

Identifiers

PMID: 29528145
DOI: 10.1002/mc.22804
PMCID: PMC5986597

Genes

BMI1
PRC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells.PMID 29528145Read ↗

BMI1: A Biomarker of Hematologic MalignanciesSemantic proximity Read ↗

BMI1 as a novel target for drug discovery in cancerSemantic proximity Read ↗

BMI-1, a promising therapeutic target for human cancerSemantic proximity Read ↗

BMI ‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypesSemantic proximity Read ↗

Deletion analysis of BMI1 oncoprotein identifies its negative regulatory domainSemantic proximity Read ↗

BMI1 Polycomb Group Protein Acts as a Master Switch for Growth and Death of Tumor Cells: Regulates TCF4-Transcriptional Factor-Induced BCL2 SignalingSemantic proximity Read ↗

BMI-1 Promotes Ewing Sarcoma Tumorigenicity Independent of <i>CDKN2A</i> RepressionSemantic proximity Read ↗

Momordicae Semen inhibits migration and induces apoptotic cell death by regulating c-Myc and CNOT2 in human pancreatic cancer cellsSemantic proximity Read ↗

Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer.Semantic proximity Read ↗

Synthesis of Cyanoenone-Modified Diterpenoid Analogs as Novel Bmi-1-Mediated Antitumor AgentsSemantic proximity Read ↗

Loss of the human polycomb group protein BMI1 promotes cancer-specific cell deathSemantic proximity Read ↗

Repression of Noxa by Bmi1 contributes to deguelin‐induced apoptosis in non‐small cell lung cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.